The Access to Advanced Health Institute (AAHI) has received an $18 million award from the National Institutes of Health (NIH) to develop a temperature stable, single-dose vaccine candidate for the chikungunya virus. The vaccine uses RNA platform technology to protect against the virus, a major cause of morbidity and mortality in Asia, Africa, and Latin America for which no vaccine exists. AAHI’s approach to an RNA vaccine against chikungunya is distinctly different from the RNA vaccines which...